KOBAYASHI PHARMACEUTICAL  CO.,LTD. Logo

KOBAYASHI PHARMACEUTICAL CO.,LTD.

Develops, manufactures, and markets OTC pharmaceuticals, health, and household goods.

4967 | T

Overview

Corporate Details

ISIN(s):
JP3301100008
LEI:
Country:
Japan
Address:
大阪市中央区道修町4丁目4番10号

Description

Kobayashi Pharmaceutical Co., Ltd. is a company engaged in the development, manufacturing, and marketing of a wide range of consumer products. Its core business segments include over-the-counter (OTC) pharmaceuticals, health and personal care items, and household goods. The company's diverse product portfolio features items such as nutritional supplements, deodorizing air fresheners, and disposable body warmers. Kobayashi Pharmaceutical focuses on creating innovative and niche products designed to solve specific, everyday problems for consumers, reflecting its brand slogan, 'You make a wish and we make it happen'.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2021-05-13 07:45
四半期報告書-第104期第1四半期(令和3年1月1日-令和3年3月31日)
Japanese 169.8 KB
2021-03-26 06:06
確認書
Japanese 8.2 KB
2021-03-26 06:05
内部統制報告書-第103期(令和2年1月1日-令和2年12月31日)
Japanese 22.4 KB
2021-03-26 06:04
有価証券報告書-第103期(令和2年1月1日-令和2年12月31日)
Japanese 1.2 MB
2020-11-11 01:57
四半期報告書-第103期第3四半期(令和2年7月1日-令和2年9月30日)
Japanese 199.7 KB
2020-08-07 03:26
四半期報告書-第103期第2四半期(令和2年4月1日-令和2年6月30日)
Japanese 230.5 KB
2020-05-13 08:20
四半期報告書-第103期第1四半期(令和2年1月1日-令和2年3月31日)
Japanese 174.7 KB
2020-03-27 05:18
有価証券報告書-第102期(平成31年1月1日-令和1年12月31日)
Japanese 1.1 MB
2019-11-14 05:50
四半期報告書-第102期第3四半期(2019/07/01-2019/09/30)
Japanese 180.4 KB
2019-08-08 08:02
四半期報告書-第102期第2四半期(2019/04/01-2019/06/30)
Japanese 225.9 KB
2019-05-10 04:30
四半期報告書-第102期第1四半期(2019/01/01-2019/03/31)
Japanese 168.4 KB
2019-03-28 06:09
有価証券報告書-第101期(平成30年1月1日-平成30年12月31日)
Japanese 1.1 MB
2018-11-13 04:37
四半期報告書-第101期第3四半期(2018/07/01-2018/09/30)
Japanese 211.8 KB
2018-08-07 02:13
四半期報告書-第101期第2四半期(2018/04/01-2018/06/30)
Japanese 254.8 KB
2018-05-09 03:29
四半期報告書-第101期第1四半期(2018/01/01-2018/03/31)
Japanese 201.6 KB

Automate Your Workflow. Get a real-time feed of all KOBAYASHI PHARMACEUTICAL CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KOBAYASHI PHARMACEUTICAL CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KOBAYASHI PHARMACEUTICAL CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.